The Centers for Medicare and Medicaid Services (CMS) has approved and granted a new ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) code for NeuroOne Medical Technologies' OneRF Ablation procedure.

医疗保险和医疗补助服务中心（CMS）已批准并授予NeuroOne Medical Technologies OneRF消融程序的新ICD-10-PCS（国际疾病分类，第10版，程序编码系统）代码。

The new code is 00503Z4 Destruction of Brain Using Stereoelectroencephalographic Radiofrequency Ablation, Percutaneous Approach. This code allows hospital reporting of inpatient procedures that are performed using the OneRF Ablation system, which has U.S. Food and Drug Administration (FDA) 510(k) clearance for creation of radiofrequency (RF) lesions in nervous tissue for functional neurosurgical procedures.

新代码是00503Z4使用立体脑电图射频消融，经皮途径破坏大脑。该代码允许医院报告使用OneRF消融系统进行的住院手术，该系统具有美国食品和药物管理局（FDA）510（k）的许可，可在神经组织中产生射频（RF）病变，用于功能性神经外科手术。

ICD-10-PCS codes play a critical role in the healthcare system, ensuring efficient and accurate documentation, billing, and analysis. The code takes effect Oct. 1..

ICD-10-PCS代码在医疗保健系统中起着至关重要的作用，可确保高效准确的文档记录、计费和分析。该准则于10月1日生效。。

“We are pleased that CMS has provided an ICD-10-PCS code that describes our OneRF procedure, which we believe will drive better recognition of our technology and greater utilization within the healthcare system,” NeuroOne Medical CEO Dave Rosa said. “In our view, CMS approval of our new code is a critical step in facilitating broader market acceptance of our technology’s potential to reduce hospital stays, numbers of surgeries, and adverse events, while offering enhanced patient safety.”.

NeuroOne Medical首席执行官戴夫·罗莎（DaveRosa）说：“我们很高兴CMS提供了一个描述我们OneRF程序的ICD-10-PCS代码，我们相信这将推动我们的技术得到更好的认可，并在医疗保健系统中得到更大的利用。”。“在我们看来，CMS批准我们的新代码是促进更广泛的市场接受我们的技术的潜力，以减少住院时间，手术次数和不良事件，同时提高患者安全性的关键一步。”。

The OneRF Ablation System is NeuroOne’s first device with a therapeutic indication and its third FDA 510(k)-cleared device. NeuroOne now boasts a full line of thin film electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode.

OneRF消融系统是NeuroOne的第一个具有治疗适应症的设备，也是其第三个FDA 510（k）许可的设备。NeuroOne现在拥有全套薄膜电极技术，可以解决需要诊断性大脑定位程序以及使用相同sEEG电极进行射频消融的患者。

In addition to the OneRF Ablation System, NeuroOne’s other FDA-cleared devices include the Evo cortical and sEEG electrode product lines which are used primarily for stimulation, recording and monitoring of electrical activity in the brain for less than 30 days..

除了OneRF消融系统外，NeuroOne的其他FDA批准的设备还包括Evo皮质和sEEG电极产品线，这些产品线主要用于刺激，记录和监测大脑中不到30天的电活动。。

NeuroOne estimates the current brain ablation market to be at least $100 million worldwide and growing rapidly, with the potential to grow multifold based on large addressable patient populations with unmet clinical needs.

NeuroOne估计，目前全球脑消融市场至少为1亿美元，并且增长迅速，基于大量可解决的临床需求未得到满足的患者群体，有可能增长多倍。

NeuroOne Medical Technologies Corporation is a developmental stage company that provides minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs.

NeuroOne Medical Technologies Corporation是一家处于发展阶段的公司，为患有癫痫，帕金森氏病，肌张力障碍，原发性震颤，背部手术失败引起的慢性疼痛以及其他可能改善患者预后并降低手术成本的相关神经系统疾病的患者提供EEG记录，脑刺激和消融解决方案的微创和高清解决方案。

The company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. .

该公司还可能寻求其他领域的应用，如抑郁症、情绪障碍、疼痛、尿失禁、高血压和人工智能。。